Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA clears Selvita's IND application to conduct phase I study of SEL-120

March 27, 2019

ONO-ST-468 suppresses excessive GH secretion in GHRH/arginine-induced GH hypersecretion model

March 27, 2019

New mutations found in a case of idiopathic hypogonadotropic hypogonadism

March 27, 2019

Phase III ALLEVIATE study of reproxalap meets the primary and key secondary endpoint

March 27, 2019

Lutris Pharma initiates phase I study of LUT-014 in patients with mCRC

March 27, 2019

Enrollment ongoing in phase II study of recombinant subunit tuberculosis vaccine GamTBvac

March 27, 2019

Obesity, insulin resistance bring on blood-brain barrier breakdown

March 27, 2019

An orchestrated nuclear phosphoinositide kinase complex regulates p53 stabilization

March 27, 2019

Synthetic lethal strategy for pancreatic cancer

March 27, 2019

ADC targets wild-type and mutated ALK

March 27, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...